GlobalData on MSN5mon
EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity
Innovent Biologics has released more data from two Phase III trials evaluating mazdutide in adults with type 2 diabetes and ...
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
pharmaphorum1d
Innovent throws its hat further into China's GLP-1 ring
Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly.